Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.
Who will be affected?
Readers: No access to all 28 journals. We recommend accessing our articles via PubMed Central
Authors: No access to the submission form or your user account.
Reviewers: No access to your user account. Please download manuscripts you are reviewing for offline reading before Wednesday, July 01, 2020 at 7:00 PM.
Editors: No access to your user account to assign reviewers or make decisions.
Copyeditors: No access to user account. Please download manuscripts you are copyediting before Wednesday, July 01, 2020 at 7:00 PM.
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
An integrated model to improve medication reconciliation in oncology: the PROF-1 trial
Alessandro Passardi;
Patrizia Serra;
Caterina Donati;
Federica Fiori;
Sabrina Prati;
Roberto Vespignani;
Gabriele Taglioni;
Patrizia Farfaneti Ghetti;
Giovanni Martinelli;
Oriana Nanni;
Mattia Altini;
Giovanni Luca Frassineti;
Martina Minguzzi
ABSTRACT
Background:
Background:
Aaccurate medication reconciliation reduces drug incompatibilities and adverse events that can arise at all transitions in care, putting clinical and economic outcomes at risk. Community Pharmacies (CP) are a crucial hub in the drug system, with ease and competence in gathering information for a complete and accurate recognition of conventional and supplementary drugs used at home.
Objective:
An alliance between a cancer institute (IRST) and CPs was set up to entrust the pharmacological survey to the latter and integrate the national electronic platform of private pharmacies with the oncologic electronic medical record.
Methods:
Cancer patients receiving an oncologic treatment were asked to choose a pharmacy participating to the trial, and to perform the pharmacological recognition. This was sent through the new IT platform to the electronic medical record of IRST, and the oncologist performed the reconciliation.
Results:
66 CP sent the surveys referred to 134 patients. It emerged an average of 5.9 drugs per patient used at home, with peaks of 12 and more in the most advanced age groups, and the use, in 60% of patients, of phytotherapeutic substances or standardized critical foods. Some potential interactions between non conventional medications and oncologic treatments were reported.
Conclusions:
PROF1 provided an alliance between IRST and the CP to improve medication reconciliation in healthcare transitions, and permitted to validate a new integrated IT platform. Clinical Trial: NCT04796142
Citation
Please cite as:
Passardi A, Serra P, Donati C, Fiori F, Prati S, Vespignani R, Taglioni G, Farfaneti Ghetti P, Martinelli G, Nanni O, Altini M, Frassineti GL, Minguzzi M
An Integrated Model to Improve Medication Reconciliation in Oncology: Prospective Interventional Study